Article (Scientific journals)
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe.
Terpos, Evangelos; Zambello, Renato; Leleu, Xavier et al.
2022In Cancers, 14, p. 5311
Peer Reviewed verified by ORBi


Full Text
Author postprint (490.08 kB)

All documents in ORBi are protected by a user license.

Send to


Keywords :
carfilzomib; multiple myeloma; proteasome inhibitor; real world; relapsed/refractory
Abstract :
[en] This prospective, observational study examined the real-world use of carfilzomib across 11 European countries in adults with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy. Carfilzomib and dexamethasone (Kd) use, effectiveness and safety were analyzed. In total, 271 patients received Kd among 701 adults enrolled. The median relative dose intensity of carfilzomib was 82.7% (20/56 mg/m(2), twice weekly). The overall response rate (ORR) to Kd was 68.8% (95% confidence interval [CI], 62.7-74.5): 79.2% in second line (2L), 71.6% in third line (3L) and 63.1% in fourth line or later (4L+). The ORR was 59.9% (95% CI, 51.1-68.1) in the lenalidomide-refractory subgroup and 67.7% (95% CI, 48.6-83.3) in the not lenalidomide-refractory subgroup. In the anti-CD38 refractory subgroup, the ORR was 51.6% (95% CI, 38.6-64.5); ORRs were higher when Kd was received at 2L/3L (66.7%) than at 4L+ (49.1%). Overall, patients were treated for a median time of 7.7 months. One-fifth of patients reported treatment-related treatment-emergent adverse events (≥grade 3), with a safety profile consistent with previous clinical trials. This study demonstrated the real-world use, effectiveness and safety of Kd in patients with RRMM. Despite the increasing number of new therapeutic strategies to treat RRMM, Kd remains a safe and effective option, even for older, frail and lenalidomide- or anti-CD38 mAb-refractory patients.
Disciplines :
Author, co-author :
Terpos, Evangelos ;  Department of Clinical Therapeutics, School of Medicine, National and
Zambello, Renato ;  Hematology and Clinical Immunology Branch, Department of Medicine, University of
Leleu, Xavier;  Department of Hematology, University Hospital Center La Miletrie and Inserm, CIC
Kuehr, Thomas;  Department of Internal Medicine IV, Academic Teaching Hospital Wels-Grieskirchen,
Badelita, Sorina N;  Fundeni Clinical Institute, 72437 Bucharest, Romania.
Katodritou, Eirini ;  Department of Hematology, Theagenio Cancer Hospital, 54007 Thessaloniki, Greece.
Brescianini, Alessandra;  Amgen (Europe) GmbH, 6343 Rotkreuz, Switzerland.
Liang, Tony;  Parexel International, Taipei 11071, Taiwan.
Wetten, Sally;  Amgen Ltd., Uxbridge UB8 1DH, UK.
Caers, Jo  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Language :
Title :
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe.
Publication date :
28 October 2022
Journal title :
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Ch
Volume :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 03 January 2023


Number of views
51 (3 by ULiège)
Number of downloads
27 (1 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi